CN1291729C - Antiviral Chinese medicine prepn of Hypericum perforatumand its prepn process - Google Patents
Antiviral Chinese medicine prepn of Hypericum perforatumand its prepn process Download PDFInfo
- Publication number
- CN1291729C CN1291729C CN 03125600 CN03125600A CN1291729C CN 1291729 C CN1291729 C CN 1291729C CN 03125600 CN03125600 CN 03125600 CN 03125600 A CN03125600 A CN 03125600A CN 1291729 C CN1291729 C CN 1291729C
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine preparation
- herba hyperici
- hyperici monogyni
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention belongs to a compound traditional Chinese medicine preparation prepared from Chinese herbal medicine and medical auxiliary materials, and a preparing technology thereof. The compound traditional Chinese medicine preparation comprises: 5 to 35 parts of hypericum perforatum, 3 to 21 parts of chicory, 3 to 21 parts of great burdock achene, 2.5 to 18 parts of radix ligustici sinensis, 2.5 to 18 parts of licorice root, 33 to 67 parts of lactose, 2.3 to 4.6 parts of, beta-cyclodextrin, and 1 to 2 parts of proteoglycan. The finished product is a brown yellow granule with perfume and slight bitter taste, and has the effects of clearing away heat and toxic material, dissipating dampness, eliminating turbid pathogen, dispersing depression and dissipating blood stasis, etc. The compound traditional Chinese medicine preparation is mainly used for treating hepatitis B, and has the obvious inhibited effect on 2.2.15 cell secretion HBsAg, 2.2.15 cell secretion HBeAg and HBV-DNA replication. In addition, the compound traditional Chinese medicine preparation has the functions of protecting the liver, reducing enzyme and regulating immunity.
Description
Technical field the present invention relates to a kind of medicine configuration product, particularly belongs to a kind of Chinese traditional compound medicine by Chinese herbal medicine and excipient substance preparation.
The background technology Traditional Chinese medical theory is attached great importance to the mediation of QI and blood, and gas helps blood capable, and the capable then blood of gas is capable, and the stagnation of QI is blood stasis then, and blood stasis then causes the stagnation of QI, forms the imbalance of healthy energy loss regulating YIN and YANG.And the liver belonging to wood, main store blood, main catharsis, property happiness bar reach, and as the positive QI-insufficiency of body, damp and hot epidemic miasma is taken advantage of a weak point, or unhygienic diet, or internal injury caused by excess of seven emotions, receives fortune to making taste lose it, and liver and gall are lost its catharsis and fallen ill.Therefore, treatment hepatitis B and hepatitis B virus carriers are many is main with " blood circulation promoting and blood stasis dispelling, depressed liver-energy dispersing and QI regulating, drying damp and strengthening spleen stomach function regulating ".The main uses of Herba Hyperici Monogyni is the treatment depression, simultaneously treatment slow virus and common skin diseases there is certain help, its extract can be treated hepatitis C, chronic hepatitis C and relevant viral disease thereof, but does not see the document record that is used for the treatment of hepatitis B and hepatitis B virus carriers.
Summary of the invention the invention provides a kind of Herba Hyperici Monogyni anti virus herb preparation, be the Chinese traditional compound medicine that is used for the treatment of hepatitis B and hepatitis B virus carriers, wherein contain 5～35 parts of Herba Hyperici Monogynis, 3～21 parts of Herba Cichoriis, 3～21 parts of Fructus Arctiis, 2.5～18 parts of Rhizoma Ligusticis, 2.5～18 parts in Radix Glycyrrhizae.Wherein, Herba Hyperici Monogyni can clear sharp dampness-heat of the liver, removes the epidemic disease poison, again can dissipating blood stasis, and effect is comprehensive, is monarch drug in the side; The clear sharp dampness-heat of the liver of Herba Cichorii energy is ministerial drug in the side; Fructus Arctii is the pent-up of wet dissipation epidemic disease due to heat pathogen poison clearly, lets out the epidemic disease caused by damp-heat pathogen poison clearly, can prevent the change of disease development of epidemic disease caused by damp-heat pathogen poison again; Rhizoma Ligustici can dispersing the stagnated live-QI to relieve the stagnation of QI, can ward off dirty dehumidifying again, and Fructus Arctii and Rhizoma Ligustici two flavor medicines all can cooperate monarch, ministerial drug to be used to strengthen therapeutical effect, are adjuvant drug in the side; Radix Glycyrrhizae can harmonizing the spleen and stomach, more can the side of coordination in the therapeutical effect of other all medicine, be messenger drug in the side.Also contain 33～67 parts of forming agent lactose, 2.3～4.6 parts of inclusion agents beta-schardinger dextrin-s, 1～2 part of correctives protein sugar in the side, its dosage form is granule or powder.Its preparation technology carries out according to the following steps: 1. Herba Hyperici Monogyni is ground into coarse grain, adds 6～8 times of amount 60～80% ethanol, refluxes 2～3 times, and each 1～2 hour, filtration, merging filtrate, and concentrating under reduced pressure gets clear paste-1, standby; 2. get the Rhizoma Ligustici coarse powder, add 8～10 times of water gagings and soaked distillating extracting oil 6～8 hours, the volatile oil beta-cyclodextrin inclusion compound of extraction 4～8 hours, cold preservation, sucking filtration, drying below 40 ℃ 4～6 hours, porphyrize, it is standby to cross 120 mesh sieves, 8～10 times of water gagings of medicinal residues reuse boiled 1 hour, filtered, and the aqueous solution after filtrate and the distillation merges standby.3. the Herba Hyperici Monogyni medicinal residues mix with Fructus Arctii, Herba Cichorii, Radix Glycyrrhizae three flavors, add 10 times of water gagings and decoct each 1 hour 3 times, collecting decoction filters, and filtrate and Rhizoma Ligustici decocting liquid merge, be evaporated to 2 times of crude drug amount, be cooled to room temperature, add ethanol and make pure content reach 50%, stir, left standstill 24 hours, filter, decompression recycling ethanol gets clear paste-2.4. clear paste-1 and clear paste-2 are merged, mixing adds Benexate Hydrochloride, lactose and protein sugar and granulates.
The present invention is a brown yellow granule, gas perfume (or spice), mildly bitter flavor, has heat-clearing and toxic substances removing, change temperature and ward off effects such as dirty, thin strongly fragrant dissipating blood stasis, cure mainly hepatitis B, the inhibitory action significantly of having duplicated to 2.2.15 emiocytosis HBsAg, HBeAg and HBV-DNA, and the liver protecting and ALT lowering and immunoregulatory effect are arranged, every bag of 6.0g is grown up each 1 bag, every day 3 times, 3～6 months is a course of treatment.
The experiment of duckling hepatitis B model (see Table 1, table 2).
The duck body treatment by oral administration of medicines that table 1. compound recipe Herba Hyperici Monogyni antiviral granule infects at dhbv dna
Treatment group and the clear DHBV-DNA OD of viral infection matched group Sanguis Anas domestica value are relatively
Statistical disposition: administration group different time (T
5, T
10, P
3) the clear DHBV-DNA OD of Sanguis Anas domestica value and the preceding (T of infection
0) OD value comparison (paired t-test), * p＜0.05, * * p＜0.01.
| The experiment batch | Group | Dosage g/kg bid * 10 | Duck number (only) | The clear DHBV-DNA OD490 of Sanguis Anas domestica (X ± SD) | |||
| T 0 | T 5 | T 10 | P 3 | ||||
| I | Normal saline compound recipe Herba Hyperici Monogyni | - 0.75 3.00 9.00 | 6 6 6 6 | 1.137±0.08 0.981±0.03 1.570±0.15 0.965±0.08 | 1.031±0.09 0.849±0.07 ** 1.025±0.17 ** 0.839±0.07 ** | 1.081±0.19 0.845±0.04 ** 1.069±0.21 ** 0.780±0.05 ** | 1.007±0.21 0.846±0.08 ** 1.290±0.24 ** 0.908±0.05 * |
| II | Normal saline compound recipe Herba Hyperici Monogyni | - 0.75 3.00 9.00 | 6 6 6 6 | 0.020±0.14 1.196±0.17 0.935±0.10 1.512±0.15 | 0.983±0.16 0.942±0.15 ** 0.800±0.13 * 1.318±0.20 ** | 0.980±0.18 0.897±0.10 ** 0.810±0.08 * 1.294±0.20 ** | 0.993±0.20 1.095±0.07 * 0.925±0.15 1.135±0.19 ** |
| III | Normal saline compound recipe Herba Hyperici Monogyni | - 0.75 3.00 9.00 | 6 6 6 6 | 0.960±0.19 0.910±0.25 0.952±0.15 0.980±0.11 | 0.985±0.10 0.801±0.01 ** 0.801±0.01 * 0.806±0.03 ** | 0.920±0.07 0.793±0.08 ** 0.721±0.13 ** 0.713±0.08 * | 0.967±0.08 0.639±0.10 ** 0.902±0.17 * 0.728±0.12 * |
| Positive control drug 3TC | 0.05 | 6 | 0.660±0.08 | 0.458±0.11 * | 0.342±0.14 * | 0.651±0.04 * | |
Table 2. hepatitis B duck model oral administered compound Herba Hyperici Monogyni antiviral granule treatment group
Comparison with the horizontal suppression ratio of the clear DHBV-DNA of viral infection matched group Sanguis Anas domestica
| The experiment batch | Medicine | Dosage g/kg bid * 10 | Duck number (only) | Suppression ratio (%) | ||
| T 5 | T 10 | P 3 | ||||
| I | Virus control compound recipe Herba Hyperici Monogyni | 0.75 3.00 9.00 | 6 6 6 6 | 9.43 17.60 * 18.20 * 18.99 * | 5.50 17.21 * 23.77 * 28.71 ** | 12.14 6.44 9.21 5.45 |
| II | Virus control compound recipe Herba Hyperici Monogyni | 0.75 3.00 9.00 | 6 6 6 6 | 3.66 13.90 ** 15.84 ** 13.00 * | 4.24 14.65 * 19.75 ** 14.83 * | 3.09 6.96 0.09 28.76 ** |
| III | Virus control compound recipe Herba Hyperici Monogyni 3TC | 0.75 3.00 9.00 50mg/kg | 6 6 6 6 6 | 5.77 12.43 * 14.26 * 18.71 ** 16.13 * | 0.97 14.71 ** 16.03 ** 25.76 ** 38.28 *** | 4.78 24.52 ** 20.20 * 26.98 ** 27.32 *** |
Statistical disposition: administration group different time (T
5, T
10, P
3) clear DHBV-DNA level of Sanguis Anas domestica and the preceding (T of infection
0) relatively suppression ratio and virus control group suppression ratio relatively (t checks in groups).
*p＜0.05，**p＜0.01，***p＜0.001。
When concentration was 125 μ g/ml, the inhibitory action that 2.2.15 emiocytosis HBsAg, HBeAg and HBV-DNA are duplicated was respectively 29.8 ± 2.3%, 36.5 ± 4.7% and 30.3 ± 8.8%, and the liver protecting and ALT lowering and immunoregulatory effect are arranged.Compare with model group, AST, ALT obviously reduce, and hepatocellular damage obviously alleviates (table 1,2,3).
The agent of table 1. compound recipe Herba Hyperici Monogyni antiviral granule is right
Carbon tetrachloride causes the protective effect of mouse liver injury.X±SD n＝10。
| Group | Dosage (g/kg) | Ccl 4(ml/kg) | ALT(u/L) | AST(u/L) |
| The upright special liver-tonic tablet group compound recipe Herba Hyperici Monogyni antiviral of normal saline model group speed | - - 0.45 1.10 3.30 9.90 | - 10.0 10.0 10.0 10.0 10.0 | 122.90±21.99 437.60±261.59 +++ 374.50±303.58 * 176.90±77.65 *** 154.60±149.3 *** 93.10±17.65 *** | 197.10±33.25 597.60±394.42 +++ 427.40±292.34 * 269.20±6.61 *** 253.30±118.41 ** 226.30±29.12 *** |
++ compare with the NS group+P＜0.01, * p＞0.05, and * * p＜0.05, compare with model group * * * p＜0.01.
The agent of table 2. compound recipe Herba Hyperici Monogyni antiviral granule is to D-Gal amine
Cause the protective effect of mouse liver injury.X±SD n＝10。
| Group | Dosage (g/kg) | D-Gal amine (ml/kg) | ALT (u/L) | AST (u/L) |
| The upright special liver-tonic tablet group compound recipe Herba Hyperici Monogyni antiviral granule of normal saline group model group speed | - - 0.45 1.10 3.30 9.90 | 0.80 0.80 0.80 0.80 0.80 | 61.6±15.7 844.0±378.0 +++ 318.7±304.1 *** 583.5±430.9 * 444.3±320.5 ** 426.9±329.6 ** | 182.1±32.0 1005.6±374.0 +++ 389.4±320.0 *** 672.3±368.6 * 563.9±367.6 ** 457.8±201.4 *** |
++ compare with the NS group+P＜0.01, * p＞0.05, and * * p＜0.05, compare with model group * * * p＜0.01.
Above-mentioned test rat granule consumption is 0.75,3.00, and 9.00g/kg.d, mice consumption are 1.10,3.30, and 9.90g/kg.d has obvious the liver protecting and ALT lowering and anti-HBV effect.
The agent of table 3. compound recipe Herba Hyperici Monogyni antiviral granule
Protective effect to immunologic liver injury.X±SD n＝10。
| Group | Dosage (g/kg) | BCG (mg/ only) | LPS (μ g/ only) | ALT (u/L) | AST (u/L) |
| The upright special liver-tonic tablet group compound recipe Herba Hyperici Monogyni antiviral granule of normal saline group model group speed | - - 0.45 1.10 3.30 9.90 | 2 2 2 2 2 | 0.75 0.75 0.75 0.75 0.75 | 71.8±7.28 117.4±48.43 +++ 68.2±22.07 *** 81.6±26.94 * 78.5±13.41 ** 72.4±13.70 ** | 182.1±32.0 322.8±155.58 +++ 216.6±67.73 * 238.0±44.72 * 232.4±43.58 * 201.7±25.41 ** |
++ compare with the NS group+P＜0.01, * p＞0.05, and * * p＜0.05, compare with model group * * * p＜0.01.
The used herbal raw material kind of specific embodiment the present invention: Herba Hyperici Monogyni is the dry herb of Guttiferae plant Herba Hyperici Monogyni, Fructus Arctii is the dry fruit of feverfew, Herba Cichorii is the aerial parts of feverfew saussurea intybus and Herba Cichorii, Radix Glycyrrhizae is the dry root and rhizome of leguminous plant Glycyrrhiza uralensis Fisch., Glycyrrhiza inflata Bat. or Glycyrrhiza glabra L., and Rhizoma Ligustici is the dry rhizome and the root of samphire Rhizoma Ligustici or Rhizoma Ligustici.
Embodiment one takes by weighing 12 parts of Herba Hyperici Monogynis, 8 parts of Herba Cichoriis, 8 parts of Fructus Arctiis, 6 parts of Rhizoma Ligusticis, 6 parts in Radix Glycyrrhizae, 3 parts of beta-schardinger dextrin-s in the prescription ratio earlier.And prepare according to the following steps: 1. Herba Hyperici Monogyni is ground into coarse grain, adds 6 times of amount 70% ethanol, refluxes 3 times, and each 1 hour, filtration, merging filtrate, and concentrating under reduced pressure gets clear paste-1, standby; 2. get the Rhizoma Ligustici coarse powder, add 8 times of water gagings and soaked distillating extracting oil 6 hours, the volatile oil beta-cyclodextrin inclusion compound of extraction 4 hours, cold preservation, sucking filtration, drying below 40 ℃ 4 hours, porphyrize, it is standby to cross 120 mesh sieves, 10 times of water gagings of medicinal residues reuse boiled 1 hour, filtered, and the aqueous solution after filtrate and the distillation merges standby; 3. the Herba Hyperici Monogyni medicinal residues mix with Fructus Arctii, Herba Cichorii, Radix Glycyrrhizae three flavors, add 10 times of water gagings and decoct each 1 hour 3 times, collecting decoction filters, and filtrate and Rhizoma Ligustici decocting liquid merge, be evaporated to 2 times of crude drug amount, be cooled to room temperature, add ethanol and make pure content reach 50%, stir, left standstill 24 hours, filter, decompression recycling ethanol gets clear paste-2; 4. clear paste-1 and clear paste-2 are merged, mixing adds Benexate Hydrochloride and makes powder.
Embodiment two takes by weighing 12 parts of Herba Hyperici Monogynis, 8 parts of Herba Cichoriis, 8 parts of Fructus Arctiis, 6 parts of Rhizoma Ligusticis, 6 parts in Radix Glycyrrhizae, 55 parts of lactose, 2.3 parts of beta-schardinger dextrin-s in the prescription ratio earlier.And prepare according to the following steps: 1., 2., 3. with embodiment one; 4. clear paste-1 and clear paste-2 are merged, mixing adds Benexate Hydrochloride, lactose granulation.
Embodiment three takes by weighing 5 parts of Herba Hyperici Monogynis, 3 parts of Herba Cichoriis, 3 parts of Fructus Arctiis, 2.5 parts of Rhizoma Ligusticis, 2.5 parts in Radix Glycyrrhizae, 33 parts of lactose, 4 parts of beta-schardinger dextrin-s, 1 part of protein sugar in the prescription ratio earlier.And prepare according to the following steps: 1. Herba Hyperici Monogyni is ground into coarse grain, adds 8 times of amount 60% ethanol, refluxes 2 times, and each 2 hours, filtration, merging filtrate, and concentrating under reduced pressure gets clear paste-1, standby; 2. get the Rhizoma Ligustici coarse powder, add 10 times of water gagings and soaked distillating extracting oil 8 hours, the volatile oil beta-cyclodextrin inclusion compound of extraction 8 hours, cold preservation, sucking filtration, drying below 40 ℃ 6 hours, porphyrize, it is standby to cross 120 mesh sieves, 8 times of water gagings of medicinal residues reuse boiled 1 hour, filtered, and the aqueous solution after filtrate and the distillation merges standby; 3. the Herba Hyperici Monogyni medicinal residues mix with Fructus Arctii, Herba Cichorii, Radix Glycyrrhizae three flavors, add 10 times of water gagings and decoct each 1 hour 3 times, collecting decoction filters, and filtrate and Rhizoma Ligustici decocting liquid merge, be evaporated to 2 times of crude drug amount, be cooled to room temperature, add ethanol and make pure content reach 50%, stir, left standstill 24 hours, filter, decompression recycling ethanol gets clear paste-2; 4. clear paste-1 and clear paste-2 are merged, mixing adds Benexate Hydrochloride, lactose and protein sugar and granulates.
Embodiment four takes by weighing 35 parts of Herba Hyperici Monogynis, 21 parts of Herba Cichoriis, 21 parts of Fructus Arctiis, 18 parts of Rhizoma Ligusticis, 18 parts in Radix Glycyrrhizae, 67 parts of lactose, 4.6 parts of beta-schardinger dextrin-s, 2 parts of protein sugar in the prescription ratio earlier.And prepare according to the following steps: 1. Herba Hyperici Monogyni is ground into coarse grain, adds 6 times of amount 80% ethanol, refluxes 3 times, and each 1 hour, filtration, merging filtrate, and concentrating under reduced pressure gets clear paste-1, standby; 2. get the Rhizoma Ligustici coarse powder, add 10 times of water gagings and soaked distillating extracting oil 6 hours, the volatile oil beta-cyclodextrin inclusion compound of extraction 6 hours, cold preservation, sucking filtration, drying below 40 ℃ 4 hours, porphyrize, it is standby to cross 120 mesh sieves, 10 times of water gagings of medicinal residues reuse boiled 1 hour, filtered, and the aqueous solution after filtrate and the distillation merges standby; 3. the Herba Hyperici Monogyni medicinal residues mix with Fructus Arctii, Herba Cichorii, Radix Glycyrrhizae three flavors, add 10 times of water gagings and decoct each 1 hour 3 times, collecting decoction filters, and filtrate and Rhizoma Ligustici decocting liquid merge, be evaporated to 2 times of crude drug amount, be cooled to room temperature, add ethanol and make pure content reach 50%, stir, left standstill 24 hours, filter, decompression recycling ethanol gets clear paste-2; 4. clear paste-1 and clear paste-2 are merged, mixing adds Benexate Hydrochloride, lactose and protein sugar and granulates.
Claims (6)
1, Herba Hyperici Monogyni anti virus herb preparation is characterized in that it is made up of following bulk drugs: Herba Hyperici Monogyni 5～35, Herba Cichorii 3～21, Fructus Arctii 3～21, Rhizoma Ligustici 2.5～18, Radix Glycyrrhizae 2.5～18.
2, Chinese medicine preparation according to claim 1 is characterized in that wherein also can adding the beta-schardinger dextrin-2.3～4.6 of weight portion.
3, Chinese medicine preparation according to claim 1 is characterized in that wherein also can adding the lactose 33～67 of weight portion.
4, Chinese medicine preparation according to claim 1 is characterized in that wherein also can adding the protein sugar 1～2 of weight portion.
5,, it is characterized in that its dosage form is granule or powder according to the described Chinese medicine preparation of arbitrary claim in the claim 1 to 4.
6, the preparation technology of Herba Hyperici Monogyni anti virus herb preparation is characterized in that raw material and step preparation that it presses the row weight portion:
1. get Herba Hyperici Monogyni 5～35 and be ground into coarse grain, add 6 times of amount 60～80% ethanol, refluxes 2～3 times, each 1～2 hour, filtration, merging filtrate, and concentrating under reduced pressure gets clear paste-1, standby;
2. get Rhizoma Ligustici 2.5～18 coarse powder, add 8～10 times of water gagings and soaked 4～8 hours, distillating extracting oil 6～8 hours, the volatile oil of extraction beta-schardinger dextrin-2.3～4.6 enclose, cold preservation, sucking filtration, drying below 40 ℃ 4～6 hours, porphyrize, it is standby to cross 120 mesh sieves, 8～10 times of water gagings of medicinal residues reuse boiled 0.5～1.5 hour, filtered, and the aqueous solution after filtrate and the distillation merges standby;
3. the Herba Hyperici Monogyni medicinal residues mix with Fructus Arctii 3～21, Herba Cichorii 3～21, Radix Glycyrrhizae 2.5～18 3 flavors, add 10 times of water gagings and decoct each 1 hour 2～3 times, collecting decoction filters, and filtrate and Rhizoma Ligustici decocting liquid merge, be evaporated to 2 times of crude drug amount, be cooled to room temperature, add ethanol and make pure content reach 50%, stir, left standstill 24 hours, filter, decompression recycling ethanol gets clear paste-2;
4. clear paste-1 and clear paste-2 are merged, mixing adds Benexate Hydrochloride, lactose 33～67 and protein sugar 1～2 and granulates.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03125600 CN1291729C (en) | 2003-09-23 | 2003-09-23 | Antiviral Chinese medicine prepn of Hypericum perforatumand its prepn process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03125600 CN1291729C (en) | 2003-09-23 | 2003-09-23 | Antiviral Chinese medicine prepn of Hypericum perforatumand its prepn process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1526427A CN1526427A (en) | 2004-09-08 |
| CN1291729C true CN1291729C (en) | 2006-12-27 |
Family
ID=34285943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03125600 Expired - Fee Related CN1291729C (en) | 2003-09-23 | 2003-09-23 | Antiviral Chinese medicine prepn of Hypericum perforatumand its prepn process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1291729C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1329059C (en) * | 2005-07-12 | 2007-08-01 | 新疆维吾尔自治区药物研究所 | Antivirus medical broth of compound Neilupaer |
| CN106924313A (en) * | 2015-12-30 | 2017-07-07 | 姚萍 | Application of the witloof in the medicine for preparing treatment virus B hepatitis |
-
2003
- 2003-09-23 CN CN 03125600 patent/CN1291729C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1526427A (en) | 2004-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200302647B (en) | Novel medicinal herbal composition for treating liver diseases. | |
| CN105535439A (en) | Traditional Chinese medicinal composition for treating pharyngitis and preparation method thereof | |
| WO2006060951A1 (en) | A pharmaceutical composition for the treatment and/or prevention of hyperlipidemia, processes for producing the same and the use thereof | |
| CN101933973B (en) | Medicinal composition for preventing and treating liver damage | |
| CN102846879B (en) | Composition for depressing blood fat | |
| CN110801486B (en) | Traditional Chinese medicine compound preparation and preparation method and application thereof | |
| CN101390970B (en) | Traditional Chinese medicine for treating hepatitis B and preparation method thereof | |
| CN1291729C (en) | Antiviral Chinese medicine prepn of Hypericum perforatumand its prepn process | |
| CN104189520A (en) | Formula and preparation method of blood fat-reducing traditional Chinese medicine preparation | |
| CN1060938C (en) | Chinese medicinal instant powder for treatment of B-hepatitis | |
| CN1106690A (en) | Medicine of curing hepatitis | |
| CN1326552C (en) | Medicine for treating viral influenza, and its prepn. method | |
| CN104771589A (en) | Traditional Chinese medicine composition for treating fatty liver and application thereof | |
| CN106309729B (en) | A kind of Chinese medicine composition adjusting chronic hepatitis immune function | |
| CN1233388C (en) | Combination of medicine for treating hepatitis | |
| CN1182858C (en) | Yangxin tea capsule and preparation method thereof | |
| CN1087617C (en) | Hepatitis curing capsule | |
| CN101385783A (en) | Huganning tablets for treating chronic and urgent liver disease and preparation method thereof | |
| CN103301380B (en) | Liver-soothing and qi-regulating traditional Chinese medicinal composition and preparation method thereof | |
| CN1559523A (en) | Naodesheng soft capsule and its preparation method | |
| CN106075229A (en) | A kind of Chinese medicinal composition preparation treating anemopyretic cold | |
| CN1048638C (en) | Xifukang Chinese herb medicine compound preparation for silicosis and its preparing method | |
| CN1899574A (en) | Chinese medicine composition for preventing and controlling liver cancer and its use | |
| CN1319411A (en) | Traditional Chinese medicine compound preparation for treating chronic hepatitis B and preparation process thereof | |
| CN114129684B (en) | Traditional Chinese medicine composition and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20061227 Termination date: 20100923 |